Patient treatments with ViewRay's MRIdian Linac begin in New England

October 07, 2019
CLEVELAND, Oct. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian® Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

"We will now be able to adapt the therapy to changes in the patient's body such as movement caused by breathing or digestion, to target cancer more accurately and deliver radiation only when the tumor is in the proper position," said Daphne Haas-Kogan, M.D., chair Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center.

The new MRI-guided radiation therapy will be used to treat many different cancer types. Its greatest potential advantage will be in treating soft-tissue tumors – including breast, gastrointestinal, gynecological, prostate, pancreas, sarcoma, and head and neck tumors – and for tumors that are highly mobile, such as lung cancers.

"This new technology offers substantial clinical benefit by providing greater resolution of soft tissue tumors, allowing for more precise tumor targeting and less radiation exposure thus sparing healthy tissue," said Raymond Mak, M.D., lead radiation oncologist for MRI-Guided Radiation Therapy at Dana-Farber/Brigham and Women's Cancer Center. "This cutting-edge technology allows us to personalize and adapt each treatment in ways we never could before."

"Dana Farber/Brigham and Women's is a world leader in adult and pediatric cancer treatment and research," said Scott Drake, President and CEO of ViewRay. "We share a common mission to eradicate cancer with the use of innovative technologies, and we look forward to further serving patients."

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

SOURCE ViewRay, Inc.